SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the βCompanyβ) (Nasdaq: KURA), a...
β KOMET-001 registrational trial in R/R NPM1-m AML achieved primary CR/CRh endpoint; topline data submitted for...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads